Posts

Posted on

Playing to WIN: CEO’s of Activision Blizzard, FansUnite, NetEase, and GAN Limited Driving New Revenue Growth Opportunities in E-Sports, and Digital Entertainment

NEW YORK, Dec. 23, 2020 (GLOBE NEWSWIRE) — Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Activision Blizzard, Inc. (NASDAQ: ATVI), NetEase (NASDAQ: NTES) FansUnite (OTC: FUNFF) (CSE: FANS), and GAN Limited (NASDAQ: GAN)

Digital Entertainment is emerging as the dominant growth theme of the decade, with billions of dollars in revenues generated worldwide from video games, streaming to online casinos and sports betting. Wall Street Reporter highlights the latest comments from industry thought leaders:

Activision Blizzard, Inc. (NASDAQ: ATVI) CEO Bobby Kotick: “Billion Dollar Entertainment Franchises – With Momentum”

“…We now expect net bookings in 2020 to grow over 25% year-over-year with earnings per share growing even faster. Since refocusing our teams on our greatest opportunities, we’ve started to return to the execution excellence, we’ve always been known for. We have significantly grown the number of creative and commercial employees working on our key franchises. …We’re in a position to deliver sustained and significant long-term expansion across our portfolio of fully owned franchises. As we execute against our content pipeline to extend our key franchises to mobile, introduce new free-to-play experiences and continue to optimize in-game operations we are positioned to continue converting our growing engagement into consistent and long-term revenue and earnings growth.”

“…Call of Duty is the first community to benefit from our pursuit of this franchise based strategy. With over 100 million monthly players, the Call of Duty community is larger than ever before. And with expansion across all platforms the franchise has transformed into a truly social experience that engages and connects our players in truly epic ways. By expanding to mobile, we’ve brought in tens of millions of new players in countries far beyond our traditional audiences. With the game now in final large-scale testing in China and over 50 million players already preregistered, we see a clear path to continue growing Call of Duty’s reach, engagement, and player investment on mobile in the largest mobile gaming market in the world.”

“…There are few entertainment franchises that generate over $1 billion in annual net bookings. And today we operate three of them: Call of Duty World of Warcraft and Candy Crush. And each has clear opportunity for sustained growth…For the balance of this year, we’re raising our outlook and we believe we will continue connecting and engaging more players than ever before in 2021.”

Activision Blizzard, Inc. (NASDAQ: ATVI) Q3 2020 Earning Highlights:


http://bit.ly/34ExR9O

FansUnite (OTC: FUNFF) (CSE: FANS) “Positioned for Exponential Revenue Growth in iGaming, E-Sports, Online Sports Betting”

In a recent presentation at Wall Street Reporter’s NEXT SUPER STOCK livestream, FansUnite (OTC: FUNFF) (CSE: FANS) CEO Scott Burton explained how the company’s latest distribution deal with a online casino games aggregator, sets the stage for exponential revenue growth opportunities. In the next 12 months, FUNFF plans to expand its current line from three games to twelve – while adding multiple aggregators for each game – reaching millions of new online casino customers worldwide. With each game generating as much as $500,000 in revenue per month for FUNFF – per online casino – and the potential to be in hundreds of online casinos – these numbers can quickly add up.

Watch FansUnite (OTC: FUNFF) NEXT SUPER STOCK 12/9/20 VIDEO:


http://bit.ly/3phwp53

December 16 – FUNFF gains first-mover advantage into the U.S. esports betting market, as it’s long-term partner GameCo joins US Bookmaking and Sky Ute Casino to establish the first dedicated esports sportsbook in the United States. FUNFF wholly-owned subsidiary Askott Entertainment will supply its iGaming platform, Chameleon, as part of a fully integrated esports betting solution. Through GameCo’s partnership with Sky Ute Casino and US Bookmaking, FansUnite will be the first iGaming solutions provider to receive significant exposure in the U.S. esports betting market.

December 7 – FUNFF receives Malta Gaming Service License and Critical Gaming Supply, and will now be able to offer a full spectrum of online gambling services in Europe, covering Casino, Fixed Odds Betting, Pool Betting and Controlled Skilled Games. With MGA approval received, FansUnite will be joining other highly respected gambling companies such as PokerStars, Betfair and Unibet in operating their business within MGA regulations.

Nov 5 – FUNFF’s wholly-owned UK Sportsbook McBookie achieves record 433% increase in revenue and 713% increase in gross margin in October 2020 compared to October 2019. Much of the growth was attributed to the unveiling of McBookie’s live casino games and increased activity in sports betting which resulted in $7.3M in total betting volume being placed during the month

Watch FansUnite (OTC: FUNFF) NEXT SUPER STOCK 12/9/20 VIDEO:


http://bit.ly/3phwp53

GAN Limited (NASDAQ: GAN) CEO Dermot Smurfit: “
On Path To $100 Million Revenue with Online Sports Betting and Casinos”

“..While both the consumer attention and client demand remains focused on sports betting, the real core of the U.S. internet gambling profit opportunity lies inherently within the online casino, which is only unlocked by the mass market appeal of sports betting being a technical and operational capability, we will shortly possess…”

“When you combine online casino gaming with internet poker, and of course, internet sports betting, New Jersey generated in excess of $132 million of gross operating revenue in that single state in the single month of October. This amount would have seemed implausible just two years ago. New Jersey is now on a path where internet gambling revenues could be on a monthly run rate to exceed pre-COVID retail gaming revenues by the end of 2022. I’ll state this again, because it is incredibly important for everyone to understand the magnitude of the structural shift in the retail casino industry. New Jersey’s internet gambling market is on a growth path to exceed pre-COVID monthly retail casino gaming revenues within 18 months, possibly less. This all points to bright line a truth that COVID combined with the advent of internet sports betting and the associated strong cross-sell of sports gamblers into online casino gaming has manifestly altered expected future growth opportunities in this industry for decades to come…Our continuing mission is to bring retail casinos online with our technology platform focused principally on delivering all forms of internet gambling content, including casino gaming and sports betting.”

“‘…The largest event in 2020 for shareholders appears not to be an admission to trading on NASDAQ, but the inflection point represented by or now announced acquisition of Coolbet with regulated operations in both Europe and Latin America…This acquisition accelerates our previously announced pathway to $100 million in topline revenues. It unlocks the shareholder value opportunity to become a B2B sports betting provider in the U.S. and provides us with a fast growing internal — international strategy, which is entirely incremental to our existing international market activity in Italy.”

GAN Limited (NASDAQ: GAN) Q3 2020 Earnings Highlights:


https://bit.ly/32QlM0m

NetEase (NASDAQ: NTES) CEO William Ding: ”Building Global Leader in Digital Entertainment”

“…We grew our net revenues year-over-year by nearly 26% to RMB18.2 billion for this quarter, and our net income from continuing operations attributable to our shareholders grew year-over-year by 35% to RMB4.5 billion.Our online games was up 21% in the second quarter year-over-year, reaching net revenue of RMB13.8 billion, driven by the impressive strength of our existing titles. Our flagship, Fantasy Westward Journey series and Westward Journey series, continued their strong performance in the second quarter. As two of the largest and longest-running game IPs in China, both games consistently attract a loyal crowd…”

“…We are very committed to bringing the richest content to Chinese users by introducing exciting global music and incubating independent musicians. In the second quarter, we launched numerous paid live shows for independent bands, giving them more options to stream online during this uncertain time…Beyond our progress in the domestic market, we have also made multiple headway with our international initiatives. Our overseas online game net revenues hit a new record high in the second quarter, propelled by robust performances from Knives Out and Life-After in Japan…”

“…NetEase is best known for our content creation capabilities. This rings true across our different business segments. As we look to the second half of this year, we are more confident and committed than ever to further expanding our reach and bringing relevant, exciting, new products and services to NetEase players, fans and followers around the world…We are excited to lead our next wave of expansion as we continue to build value for all of our stakeholders…”

NetEase (NASDAQ: NTES) Q2 2020 Earnings Highlights:


https://bit.ly/3kFMNK9

WALL STREET REPORTER

Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO’s of promising, publicly-traded companies, and market experts. www.WallStreetReporter.com

About Wall Street Reporter’s Next Super Stock conference:

Wall Street Reporter’s NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/

CONTACT:

WALL STREET REPORTER

(212) 871-2057 ext 7


www.WallStreetReporter.com



Posted on

Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients

PR Newswire

NEW YORK, Dec. 23, 2020 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-001, a topical drug formation under development for the treatment of rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.

Cancer patients receiving EGFR inhibitor therapy often require repeat courses to achieve effective cancer treatment, and >50% of patients have significant dermatological side effects within the first 2 weeks of treatment that persist even after stopping EGFR therapy. These skin toxicities can severely impact patient quality of life and can result in reduction of EGFR inhibitor dose or interruption of treatment. HT-001 is targeted to treat these EGFR-induced skin disorders to allow patients to achieve the best potential outcomes of EGFR therapy, as there are currently no approved drugs to specifically treat EGFR inhibitor-induced skin disorders.

In July 2019 Hoth Therapeutics entered into a Sponsored Research Agreement with the George Washington University (GW) to explore preclinical pharmacology studies with topically administered HT-001.

Currently in the preclinical stage of development of HT-001, Hoth Therapeutics anticipates a meeting with the FDA to be scheduled during the first quarter of 2021. HT-001 is being positioned for submission via the 505(b)(2) development pathway, in which Hoth Therapeutics intends to rely on information not obtained through right of reference in order to reduce the nonclinical and clinical program and expedite time to NDA submission. During the pre-IND meeting with the FDA, Hoth Therapeutics plans to discuss the overall proposed drug development program for HT-001 including requirements for nonclinical, clinical pharmacology, clinical, and chemistry, manufacturing, controls. Hoth also plans to present clinical trial designs for the IND-opening, phase 2a dose ranging study as well as a proposed follow-up phase 2b safety and efficacy dose extension study; both studies will be conducted in cancer patients receiving EGFR inhibitor therapy.

“Palliative care treatment for cancer patients continues to be an underserved segment of the market that our HT-001 product has an opportunity to provide patients with a better quality of life during their cancer treatment,” stated Robb Knie, Chairman and CEO of Hoth Therapeutics. “We look forward to working closely with the FDA on our Phase 2a and Phase 2b trial designs and advancing HT-001 through the research and development process.”

About Hoth Therapeutics, Inc. 
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com .

Forward-Looking Statement 
This press release includes forward-looking statements based upon Hoth’s current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth’s business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management’s expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled “Risk Factors” in Hoth’s most recent Annual Report on Form 10-K and Hoth’s other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth’s current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact: 
LR Advisors LLC 
Email: [email protected]
www.hoththerapeutics.com
Phone: (678) 570-6791

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-submits-request-for-a-pre-investigational-new-drug-pre-ind-meeting-for-ht-001-treatment-for-cancer-patients-301197951.html

SOURCE Hoth Therapeutics, Inc.

Posted on

Vanguard Announces Final Cash Distributions for the Vanguard ETFs (VBU, VBG and VGAB)

Canada NewsWire

TORONTO, Dec. 23, 2020 /CNW/ – Vanguard Investments Canada Inc. today announced the final December 2020 cash distributions for certain Vanguard ETFs, listed below, that trade on Toronto Stock Exchange (TSX).

Unitholders of record on December 24, 2020 will receive cash distributions payable on January 5, 2021. Please be advised that the distributions announced in this press release are the same as those stated in the December 17, 2020 press release for these funds.

Details of the “per unit” distribution amounts are as follows: 


Vanguard ETF®


TSX
Ticker
Symbol


Distribution
per Unit ($)


CUSIP


ISIN


Payment
Frequency

Vanguard U.S. Aggregate Bond Index ETF (CAD-
hedged)

VBU

0.067017

92206G103

CA92206G1037

Monthly

Vanguard Global ex-U.S. Aggregate Bond Index
ETF (CAD-hedged)

VBG

0.047142

92206H101

CA92206H1010

Monthly

Vanguard Global Aggregate Bond Index ETF
(CAD-hedged)

VGAB

0.053025

92211F108

 

CA92211F1080

 

Monthly

To learn more about the TSX-listed Vanguard ETFs, please visit www.vanguardcanada.ca

About Vanguard

Canadians own CAD $49 billion in Vanguard assets, including Canadian and U.S.-domiciled ETFs, Canadian institutional products and Canadian mutual funds. Vanguard Investments Canada Inc. manages CAD $31 billion in assets (as of November 30, 2020) with 37 Canadian ETFs and four mutual funds currently available. The Vanguard Group, Inc. is one of the world’s largest investment management companies and a leading provider of company-sponsored retirement plan services. Vanguard manages USD $6.3 trillion (CAD $8 trillion) in global assets, including over USD $1.4 trillion (CAD $1.8 trillion) in global ETF assets (as of October 31, 2020). Vanguard has offices in the United States, Canada, Mexico, Europe, Australia and Asia. The firm offers 421 funds, including ETFs, to its more than 30 million investors worldwide.

Vanguard operates under a unique operating structure. Unlike firms that are publicly held or owned by a small group of individuals, The Vanguard Group, Inc. is owned by Vanguard’s U.S.-domiciled funds and ETFs. Those funds, in turn, are owned by Vanguard clients. This unique mutual structure aligns Vanguard interests with those of its investors and drives the culture, philosophy, and policies throughout the Vanguard organization worldwide. As a result, Canadian investors benefit from Vanguard’s stability and experience, low-cost investing, and client focus. For more information, please visit vanguardcanada.ca.

Important information

Commissions, management fees, and expenses all may be associated with investment funds. Investment objectives, risks, fees, expenses, and other important information are contained in the prospectus; please read it before investing. Investment funds are not guaranteed, their values change frequently, and past performance may not be repeated. Vanguard funds are managed by Vanguard Investments Canada Inc. and are available across Canada through registered dealers.

SOURCE Vanguard Investments Canada Inc.

Posted on

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against OrthoPediatrics Corp. and Encourages Investors with Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against OrthoPediatrics Corp. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of OrthoPediatrics Corp. (“OrthoPediatrics” or “the Company”) (NASDAQ: KIDS) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. OrthoPediatrics is the subject of a report published by Culper Research on December 2, 2020, titled: “OrthoPediatrics Corp. (KIDS): Even Channel Stuffing Can’t Save This Company.” The report alleges that the Company has “engaged in a channel stuffing scheme that has systematically and significantly overstated revenues.” Culper adds that “the Company has abused its ability to book revenues upon shipment by selling and shipping excess product directly to its distributors, many of whom are exclusive to the Company.” Culper further states it is “concerning that many of the Company’s ‘exclusive distributors’ are simply former OrthoPediatrics employees who have formed their own distributorships, often while still employed at the Company.” Based on this report, shares of OrthoPediatrics dropped by more than 9% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm

Brian Schall, Esq.

310-301-3335

[email protected]

www.schallfirm.com

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial

PR Newswire

CHENGDU, China, Dec. 23, 2020 /PRNewswire/ — Chengdu Kanghong Pharmaceutical Group (“Kanghong”) announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomized trial (nicknamed “PANDA”) to test the efficacy and safety of conbercept intravitreal injection in the treatment of neovascular age-related macular degeneration (“nAMD”). PANDA trials recently reached an important milestone by completing 36-week primary endpoint visits of enrolled patients. Conbercept is expected to launch globally in 2023, bringing a new treatment option to patients. 

Of the more than 2.2 billion people who suffer from visual impairment or blindness around the world, AMD, glaucoma, and cataract are three leading causes. Conbercept is a new generation anti-VEGF fusion protein, approved and marketed in China as Lumitin®, for the treatment of retina diseases. Conbercept acts to inhibit the growth of new abnormal blood vessels and improve blood vessel permeability by blocking signal transmission mediated by vascular endothelial growth factor (VEGF). Anti-VEGF therapy such as conbercept is currently the standard treatment of nAMD.

After 10 years of development, Conbercept was first approved in China in 2014. In the same year, at the 11th Annual American Neovascularization Conference, a special report, “Wet AMD: Conbercept Phase III Clinical Trial Results” garnered much attention and praise from industry and clinical experts. In particular, Professor Philip J. Rosenfeld, conference Chairman, said “conbercept provides us with new opportunities for anti-VEGF drugs to prevent blindness. It is unique in structure and can provide better durability and greater effectiveness.” In the first half of this year, nearly 0.36 million people have received treatment with conbercept.

Conbercept was agreed by the Food and Drug Administration in the US in 2016 and the European Medicine Agency in 2017 to directly enter Phase III clinical trials, which was approved for FDA’s Special Protocol Assessment (SPA) in 2018. PANDA trials are conducted in more than 300 research sites across 30 countries.

More about Conbercept

Conbercept is a new generation anti-VEGF, a 100 percent humanized fusion protein that targets VEGF-B, placental growth factor (PlGF), and various isoforms of VEGF-A. In China, it was approved for the treatment of nAMD in 2014, for the treatment of pathological myopia associated with choroidal neovascularization (“pmCNV”) in 2017, and for the treatment of diabetic macular edema (“DME”) in 2019. A large number of real-world treatment and investigator-sponsored trials have shown conbercept to be safe and efficacious.

More about PANDA trials

The PANDA trials are two independent trials with similar protocols. Each trial enrolled about 1140 patients randomized into three arms: 0.5 mg of conbercept injected every 8 weeks, 1.0 mg of conbercept injected every 12 weeks, and 2.0 mg of aflibercept injected every 8 weeks as per the approved dosage. The Steering Committee of the PANDA trials is co-chaired by two world-renowned retina specialists, Dr. Peter Kaiser of Cleveland Clinic, and Dr. Jeffrey Heier of Ophthalmic Consultants of Boston.

About Chengdu Kanghong Pharmaceutical Group.

Chengdu Kanghong Pharmaceutical Group is dedicated to improving ophthalmic care through the development and commercialization of innovative products for a wide range of ocular conditions. Founded in 1996, the Group became a publicly listed company in China in 2015 and acquired IOPtima, a company in Israel dedicated to the development of ophthalmic devices. Last week, Kanghong Pharmaceutical Group announced plans to raise approximately CNY3.5 billion to fund clinical trials and registration of conbercept around the world for additional indications.

Cision View original content:http://www.prnewswire.com/news-releases/conbercept-new-generation-of-product-for-treatment-of-namd-completes-36-week-primary-endpoint-visits-of-phase-iii-trial-301197992.html

SOURCE Chengdu Kanghong Pharmaceutical Group

Posted on

Bitcoin Events’ Blockchain Africa Conference Returns to Johannesburg in March

CAPE TOWN, South Africa, Dec. 23, 2020 (GLOBE NEWSWIRE) — via CryptoCurrencyWire — Bitcoin Events’ flagship event, Blockchain Africa Conference 2021, is scheduled to take place on March 18-19, 2021, in Johannesburg, South Africa. The seventh conference in the acclaimed series, Blockchain Africa Conference 2021 is expected to attract 500 attendees representing over 35 countries, including investors, startups, enthusiasts, developers, corporations, policy makers and regulators. The event is designed to provide an ecosystem for attendees from all backgrounds to learn, network and collaborate.

This year’s conference will put a spotlight on blockchain’s continued transformation from hype to mainstream. A roster of 35 high-profile speakers will take the stage to explore how collective sentiment about blockchain technology continues to rise, particularly as tech and payment giants such as PayPal, Square and Facebook make significant investments in the space.

Since 2015, Bitcoin Events’ annual Blockchain Africa Conferences have been the first of their kind on the African continent. With massive challenges relating to processing transactions and doing business in many regions of Africa, blockchain technology is expected to provide a simpler, more efficient way of facilitating the next generation of payment infrastructure across the region.

“As blockchain technology matures, we’re seeing a shift away from blockchain experiments toward the development of robust, enterprise-ready solutions. Through Blockchain Africa Conference 2021, we’re bringing together adopters and application leaders who are using blockchain to revolutionize payments and digital business as a whole. We’re excited to play a role in this maturation and explore how blockchain can make doing business in Africa more seamless,” stated Sonya Kuhnel, Founder of Bitcoin Events.

Blockchain Africa Conference 2021 is an unparalleled opportunity for innovators, disruptors and thought leaders who want to learn, share knowledge and network with like-minded individuals. The event’s organizers expect attendees from six continents spanning multiple industries and disciplines, such as fintech, software development, telecommunications, banking and venture capital firms.

“If your business is in or with Africa and your target is growth, Blockchain Africa Conference 2021 is a must-attend event. The gathering will bring together hundreds of attendees from around the globe to discuss the future and convergence of blockchain technology and cryptocurrencies, particularly how these technologies are addressing urgent challenges in Africa,” said Theo Sauls, Founder of Bitcoin Events.

Registration for Blockchain Africa Conference 2021 is now open and available in multiple options – from live streaming tickets to startup passes and more. Both fiat and cryptocurrency payments are accepted.

To register, stay up to date on the expanding speaker list and acquire additional information, visit https://ccw.fm/BlockchainAfricaRegistration. Tickets are limited. Secure your spot now.

About Blockchain Africa Conference 2021

Since 2015, Bitcoin Events’ annual Blockchain Africa Conferences have been bringing together some of the top thought leaders from across the globe. Over 2,000 delegates and 170 speakers representing more than 40 countries have attended the previous six conferences, hailing from both the public and private sectors.

Blockchain Africa Conference 2021 will take place in Johannesburg, South Africa, on March 18-19, 2021. Over 500 attendees are expected, as well as a roster of 35 high-profile speakers. For more information, visit the event’s website at www.BlockchainAfrica.co.

For interview requests or additional information, please contact:
[email protected]

Corporate Communications

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Wire Service Contact

CryptoCurrencyWire (CCW)
New York, New York
www.CryptoCurrencyWire.com
212.994.9818 Office
[email protected]



Posted on

SUNZ Holdings, Leading Workers Compensation Insurance and Services Company, Announces Significant Investment from Blackstone Tactical Opportunities

Bradenton, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) — SUNZ Holdings, LLC (“SUNZ”) announced today that funds managed by Blackstone Tactical Opportunities (“Blackstone”) have acquired a significant stake in the company to help fuel SUNZ’s continued expansion. Terms of the transaction were not disclosed.

SUNZ is a leading provider of workers compensation insurance and related services such as policy administration, claims administration and customer support. SUNZ delivers technologically advanced solutions for its customers – with a specialized focus on risk sharing programs for Professional Employer Organizations, staffing companies and large organizations.


Menes Chee, a Senior Managing Director at Blackstone, said, “SUNZ is exceptionally well positioned for future growth. Blackstone is excited to partner with their first-rate management team to help the company continue to expand into new markets and verticals so it can best serve its customers.” 

Steve Herrig, CEO of SUNZ, said, “This partnership should propel SUNZ to a new level by enabling us to pursue new market opportunities and expand our national footprint. We look forward to a synergistic collaboration with Blackstone and to further accelerating the expansion of our specialized programs.”

About SUNZ Holdings, LLC

SUNZ Holdings, LLC is the parent company of SUNZ Insurance, a national workers’ compensation insurance company headquartered in Bradenton, Florida. SUNZ Insurance develops unique workers’ compensation programs that deliver innovative and tailored solutions to protect businesses and their employees. SUNZ understands its clients need for fluidity, offering workers’ compensation insurance options that do not begin and end with the printed policy. SUNZ believes that a safe work environment and healthy workforce is the foundation for a successful business. There are several affiliate companies within the SUNZ Holdings enterprise that provide related and ancillary services to the workers compensation insurance industry.  These companies include Next Level Administrators, WatchPoint, Avalon Subrogation Partners, and Ascential Care Partners. For more information, visit www.sunzinsurance.com.  

About Blackstone

Blackstone is one of the world’s leading investment firms. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $584 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow Blackstone on Twitter @Blackstone.

About Tactical Opportunities

Tactical Opportunities (Tac Opps) is Blackstone’s opportunistic investment platform. The Tac Opps team invests globally across asset classes, industries and geographies, seeking to identify and execute on attractive, differentiated investment opportunities. As part of the strategy, the team leverages the intellectual capital across Blackstone’s various businesses while continuously optimizing its approach in the face of ever-changing market conditions.



Matt Anderson
Blackstone
212-390-2472
[email protected]

Posted on

Thinking about trading options or stock in Pfizer, Plug Power, Carnival Corp, Canadian Solar, or Workday?

PR Newswire

NEW YORK, Dec. 23, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for PFE, PLUG, CCL, CSIQ, and WDAY.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report – Measures a stock’s suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street’s opinion including a 12-month price forecast.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-pfizer-plug-power-carnival-corp-canadian-solar-or-workday-301198106.html

SOURCE InvestorsObserver

Posted on

Thinking about buying stock in CASI Pharmaceuticals, FuelCell Energy, Ampio Pharmaceuticals, Mohawk Group, or Perion Network?

PR Newswire

NEW YORK, Dec. 23, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for CASI, FCEL, AMPE, MWK, and PERI.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-casi-pharmaceuticals-fuelcell-energy-ampio-pharmaceuticals-mohawk-group-or-perion-network-301198101.html

SOURCE InvestorsObserver

Posted on

Thinking about trading options or stock in Apple, Caesars Entertainment, Merck, AT&T, or FireEye?

PR Newswire

NEW YORK, Dec. 23, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for AAPL, CZR, MRK, T, and FEYE.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report – Measures a stock’s suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street’s opinion including a 12-month price forecast.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-apple-caesars-entertainment-merck-att-or-fireeye-301198104.html

SOURCE InvestorsObserver